The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Cann Global (CGB) shares jump after its cannabis hard pills were received in Australia
  • Cann began importing the cannabis pills in late March following the green light by Health Canada
  • Currently, two of its six products have been shipped, with the remaining four arriving soon
  • The cannabidiol formulations will be available for ordering by pharmacies once the shipment has been cleared in customs
  • On market close, Cann is up 20 per cent and trading at 0.6 cents per share

Cann Global (CGB) shares jumped today after its cannabis hard pills were received in Australia.

The company launched its products last October with its Canadian joint venture partner Canntab Therapeutics.

Cann began importing the cannabis pills in late March after receiving the green light by Health Canada.

Currently, two of its six products have been shipped, with the remaining four arriving soon.

According to Cann, its products are unique because of the patented hard pill form in which they come in, allowing for more precise dosing.

The cannabidiol formulations will be available for ordering by pharmacies once the shipment has been cleared in customs.

“The products can be prescribed by practitioners via the Special Access Scheme Category B application pathway,” the company told the market.

Cann Global will update the market when the remaining four products have arrived in Australia.

On market close, Cann is up 20 per cent and trading at 0.6 cents per share.


cgb by the numbers
More From The Market Online

Bioxyne expands LATAM medicinal cannabis footprint with Costa Rica agreement

Bioxyne has signed an agreement for the first international supply of medicinal cannabis flower into Costa…

Amplia Therapeutics and ANZGOG to undertake ovarian cancer study

Amplia Therapeutics and the ANZOG have entered into an agreement to conduct a new clinical study…

Noxopharm brings in specialist support to help progress its US regulatory strategy

Clinical-stage Australian biotech company Noxopharm (ASX:NOX) has engaged a global clinical research organisation to support it in the lead-up to a pre-investigational
The Market Online Video

FDA greenlights Syntara’s Amsulostat Phase 2b, setting up big 2026 catalysts

Syntara has had a positive outcome from its in person Type C meeting with the US…